The simultaneous inhibition of PD-1 and vascular endothelial growth factor (VEGF) pathways enhances T cell mobilization, induces immune activity in the tumor microenvironment, and synergizes with other antitumor effects [110]. Here, PDCD1 is linked to neoplasm.